nodes	percent_of_prediction	percent_of_DWPC	metapath
Betahistine—Discomfort—Mitomycin—urinary bladder cancer	0.00897	0.00897	CcSEcCtD
Betahistine—Pruritus—Valrubicin—urinary bladder cancer	0.00894	0.00894	CcSEcCtD
Betahistine—Confusional state—Mitomycin—urinary bladder cancer	0.00878	0.00878	CcSEcCtD
Betahistine—Diarrhoea—Valrubicin—urinary bladder cancer	0.00864	0.00864	CcSEcCtD
Betahistine—Dizziness—Valrubicin—urinary bladder cancer	0.00835	0.00835	CcSEcCtD
Betahistine—Vomiting—Valrubicin—urinary bladder cancer	0.00803	0.00803	CcSEcCtD
Betahistine—Rash—Valrubicin—urinary bladder cancer	0.00797	0.00797	CcSEcCtD
Betahistine—Dermatitis—Valrubicin—urinary bladder cancer	0.00796	0.00796	CcSEcCtD
Betahistine—Headache—Valrubicin—urinary bladder cancer	0.00791	0.00791	CcSEcCtD
Betahistine—Dyspnoea—Mitomycin—urinary bladder cancer	0.00776	0.00776	CcSEcCtD
Betahistine—Somnolence—Mitomycin—urinary bladder cancer	0.00774	0.00774	CcSEcCtD
Betahistine—Nausea—Valrubicin—urinary bladder cancer	0.0075	0.0075	CcSEcCtD
Betahistine—Fatigue—Mitomycin—urinary bladder cancer	0.0075	0.0075	CcSEcCtD
Betahistine—Feeling abnormal—Mitomycin—urinary bladder cancer	0.00717	0.00717	CcSEcCtD
Betahistine—Dermatitis atopic—Epirubicin—urinary bladder cancer	0.00667	0.00667	CcSEcCtD
Betahistine—Orthostatic hypotension—Cisplatin—urinary bladder cancer	0.00638	0.00638	CcSEcCtD
Betahistine—Bronchospasm—Gemcitabine—urinary bladder cancer	0.00637	0.00637	CcSEcCtD
Betahistine—Asthenia—Mitomycin—urinary bladder cancer	0.00624	0.00624	CcSEcCtD
Betahistine—Dermatitis atopic—Doxorubicin—urinary bladder cancer	0.00617	0.00617	CcSEcCtD
Betahistine—Hallucination—Thiotepa—urinary bladder cancer	0.00613	0.00613	CcSEcCtD
Betahistine—Diarrhoea—Mitomycin—urinary bladder cancer	0.00595	0.00595	CcSEcCtD
Betahistine—Dizziness—Mitomycin—urinary bladder cancer	0.00576	0.00576	CcSEcCtD
Betahistine—Stevens-Johnson syndrome—Gemcitabine—urinary bladder cancer	0.00572	0.00572	CcSEcCtD
Betahistine—Vasodilation—Epirubicin—urinary bladder cancer	0.00562	0.00562	CcSEcCtD
Betahistine—Vasodilation procedure—Epirubicin—urinary bladder cancer	0.00562	0.00562	CcSEcCtD
Betahistine—Immune system disorder—Thiotepa—urinary bladder cancer	0.00556	0.00556	CcSEcCtD
Betahistine—Vomiting—Mitomycin—urinary bladder cancer	0.00553	0.00553	CcSEcCtD
Betahistine—Rash—Mitomycin—urinary bladder cancer	0.00549	0.00549	CcSEcCtD
Betahistine—Dermatitis—Mitomycin—urinary bladder cancer	0.00548	0.00548	CcSEcCtD
Betahistine—Ventricular extrasystoles—Epirubicin—urinary bladder cancer	0.00547	0.00547	CcSEcCtD
Betahistine—Headache—Mitomycin—urinary bladder cancer	0.00545	0.00545	CcSEcCtD
Betahistine—Bronchospasm—Etoposide—urinary bladder cancer	0.00544	0.00544	CcSEcCtD
Betahistine—Vasodilation—Doxorubicin—urinary bladder cancer	0.0052	0.0052	CcSEcCtD
Betahistine—Vasodilation procedure—Doxorubicin—urinary bladder cancer	0.0052	0.0052	CcSEcCtD
Betahistine—Nausea—Mitomycin—urinary bladder cancer	0.00517	0.00517	CcSEcCtD
Betahistine—Ventricular extrasystoles—Doxorubicin—urinary bladder cancer	0.00506	0.00506	CcSEcCtD
Betahistine—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.0049	0.0049	CcSEcCtD
Betahistine—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.00489	0.00489	CcSEcCtD
Betahistine—Immune system disorder—Gemcitabine—urinary bladder cancer	0.00468	0.00468	CcSEcCtD
Betahistine—Convulsion—Thiotepa—urinary bladder cancer	0.00465	0.00465	CcSEcCtD
Betahistine—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.00453	0.00453	CcSEcCtD
Betahistine—Confusional state—Thiotepa—urinary bladder cancer	0.00441	0.00441	CcSEcCtD
Betahistine—Immune system disorder—Cisplatin—urinary bladder cancer	0.00436	0.00436	CcSEcCtD
Betahistine—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00429	0.00429	CcSEcCtD
Betahistine—Tachycardia—Thiotepa—urinary bladder cancer	0.00427	0.00427	CcSEcCtD
Betahistine—Skin disorder—Thiotepa—urinary bladder cancer	0.00425	0.00425	CcSEcCtD
Betahistine—Ill-defined disorder—Gemcitabine—urinary bladder cancer	0.00419	0.00419	CcSEcCtD
Betahistine—Erythema multiforme—Etoposide—urinary bladder cancer	0.00418	0.00418	CcSEcCtD
Betahistine—Flatulence—Cisplatin—urinary bladder cancer	0.00414	0.00414	CcSEcCtD
Betahistine—Malaise—Gemcitabine—urinary bladder cancer	0.00407	0.00407	CcSEcCtD
Betahistine—Immune system disorder—Etoposide—urinary bladder cancer	0.004	0.004	CcSEcCtD
Betahistine—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.0039	0.0039	CcSEcCtD
Betahistine—Somnolence—Thiotepa—urinary bladder cancer	0.00389	0.00389	CcSEcCtD
Betahistine—Dyspepsia—Thiotepa—urinary bladder cancer	0.00385	0.00385	CcSEcCtD
Betahistine—Convulsion—Fluorouracil—urinary bladder cancer	0.00384	0.00384	CcSEcCtD
Betahistine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00381	0.00381	CcSEcCtD
Betahistine—Discomfort—Gemcitabine—urinary bladder cancer	0.00379	0.00379	CcSEcCtD
Betahistine—Malaise—Cisplatin—urinary bladder cancer	0.00379	0.00379	CcSEcCtD
Betahistine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00378	0.00378	CcSEcCtD
Betahistine—Fatigue—Thiotepa—urinary bladder cancer	0.00377	0.00377	CcSEcCtD
Betahistine—Discomfort—Fluorouracil—urinary bladder cancer	0.00373	0.00373	CcSEcCtD
Betahistine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00368	0.00368	CcSEcCtD
Betahistine—Confusional state—Fluorouracil—urinary bladder cancer	0.00365	0.00365	CcSEcCtD
Betahistine—Convulsion—Cisplatin—urinary bladder cancer	0.00364	0.00364	CcSEcCtD
Betahistine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00362	0.00362	CcSEcCtD
Betahistine—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00361	0.00361	CcSEcCtD
Betahistine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00361	0.00361	CcSEcCtD
Betahistine—Skin disorder—Gemcitabine—urinary bladder cancer	0.00358	0.00358	CcSEcCtD
Betahistine—Ill-defined disorder—Etoposide—urinary bladder cancer	0.00357	0.00357	CcSEcCtD
Betahistine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00356	0.00356	CcSEcCtD
Betahistine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00355	0.00355	CcSEcCtD
Betahistine—Discomfort—Cisplatin—urinary bladder cancer	0.00354	0.00354	CcSEcCtD
Betahistine—Tachycardia—Fluorouracil—urinary bladder cancer	0.00353	0.00353	CcSEcCtD
Betahistine—Urticaria—Thiotepa—urinary bladder cancer	0.00348	0.00348	CcSEcCtD
Betahistine—Malaise—Etoposide—urinary bladder cancer	0.00347	0.00347	CcSEcCtD
Betahistine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00343	0.00343	CcSEcCtD
Betahistine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00337	0.00337	CcSEcCtD
Betahistine—Tachycardia—Cisplatin—urinary bladder cancer	0.00335	0.00335	CcSEcCtD
Betahistine—Convulsion—Etoposide—urinary bladder cancer	0.00334	0.00334	CcSEcCtD
Betahistine—Skin disorder—Cisplatin—urinary bladder cancer	0.00333	0.00333	CcSEcCtD
Betahistine—Asthma—Methotrexate—urinary bladder cancer	0.00331	0.00331	CcSEcCtD
Betahistine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00328	0.00328	CcSEcCtD
Betahistine—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.00327	0.00327	CcSEcCtD
Betahistine—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.00327	0.00327	CcSEcCtD
Betahistine—Somnolence—Gemcitabine—urinary bladder cancer	0.00327	0.00327	CcSEcCtD
Betahistine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00326	0.00326	CcSEcCtD
Betahistine—Discomfort—Etoposide—urinary bladder cancer	0.00324	0.00324	CcSEcCtD
Betahistine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00323	0.00323	CcSEcCtD
Betahistine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00322	0.00322	CcSEcCtD
Betahistine—Somnolence—Fluorouracil—urinary bladder cancer	0.00322	0.00322	CcSEcCtD
Betahistine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00319	0.00319	CcSEcCtD
Betahistine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00318	0.00318	CcSEcCtD
Betahistine—Fatigue—Gemcitabine—urinary bladder cancer	0.00317	0.00317	CcSEcCtD
Betahistine—Confusional state—Etoposide—urinary bladder cancer	0.00317	0.00317	CcSEcCtD
Betahistine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00314	0.00314	CcSEcCtD
Betahistine—Asthenia—Thiotepa—urinary bladder cancer	0.00314	0.00314	CcSEcCtD
Betahistine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00313	0.00313	CcSEcCtD
Betahistine—Abdominal distension—Epirubicin—urinary bladder cancer	0.00312	0.00312	CcSEcCtD
Betahistine—Asthma—Epirubicin—urinary bladder cancer	0.0031	0.0031	CcSEcCtD
Betahistine—Pruritus—Thiotepa—urinary bladder cancer	0.0031	0.0031	CcSEcCtD
Betahistine—Tachycardia—Etoposide—urinary bladder cancer	0.00307	0.00307	CcSEcCtD
Betahistine—Dyspnoea—Cisplatin—urinary bladder cancer	0.00306	0.00306	CcSEcCtD
Betahistine—Skin disorder—Etoposide—urinary bladder cancer	0.00305	0.00305	CcSEcCtD
Betahistine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00303	0.00303	CcSEcCtD
Betahistine—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.00303	0.00303	CcSEcCtD
Betahistine—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.00303	0.00303	CcSEcCtD
Betahistine—Diarrhoea—Thiotepa—urinary bladder cancer	0.00299	0.00299	CcSEcCtD
Betahistine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00298	0.00298	CcSEcCtD
Betahistine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00296	0.00296	CcSEcCtD
Betahistine—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.00293	0.00293	CcSEcCtD
Betahistine—Dizziness—Thiotepa—urinary bladder cancer	0.00289	0.00289	CcSEcCtD
Betahistine—Abdominal distension—Doxorubicin—urinary bladder cancer	0.00289	0.00289	CcSEcCtD
Betahistine—Urticaria—Fluorouracil—urinary bladder cancer	0.00288	0.00288	CcSEcCtD
Betahistine—Asthma—Doxorubicin—urinary bladder cancer	0.00287	0.00287	CcSEcCtD
Betahistine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00283	0.00283	CcSEcCtD
Betahistine—Dyspnoea—Etoposide—urinary bladder cancer	0.0028	0.0028	CcSEcCtD
Betahistine—Somnolence—Etoposide—urinary bladder cancer	0.00279	0.00279	CcSEcCtD
Betahistine—Vomiting—Thiotepa—urinary bladder cancer	0.00278	0.00278	CcSEcCtD
Betahistine—Rash—Thiotepa—urinary bladder cancer	0.00276	0.00276	CcSEcCtD
Betahistine—Dermatitis—Thiotepa—urinary bladder cancer	0.00276	0.00276	CcSEcCtD
Betahistine—Headache—Thiotepa—urinary bladder cancer	0.00274	0.00274	CcSEcCtD
Betahistine—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.00274	0.00274	CcSEcCtD
Betahistine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00271	0.00271	CcSEcCtD
Betahistine—Fatigue—Etoposide—urinary bladder cancer	0.00271	0.00271	CcSEcCtD
Betahistine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00267	0.00267	CcSEcCtD
Betahistine—Asthenia—Gemcitabine—urinary bladder cancer	0.00264	0.00264	CcSEcCtD
Betahistine—Pruritus—Gemcitabine—urinary bladder cancer	0.0026	0.0026	CcSEcCtD
Betahistine—Nausea—Thiotepa—urinary bladder cancer	0.0026	0.0026	CcSEcCtD
Betahistine—Feeling abnormal—Etoposide—urinary bladder cancer	0.00259	0.00259	CcSEcCtD
Betahistine—Pruritus—Fluorouracil—urinary bladder cancer	0.00256	0.00256	CcSEcCtD
Betahistine—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.00253	0.00253	CcSEcCtD
Betahistine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00253	0.00253	CcSEcCtD
Betahistine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00252	0.00252	CcSEcCtD
Betahistine—Erythema multiforme—Methotrexate—urinary bladder cancer	0.00251	0.00251	CcSEcCtD
Betahistine—Urticaria—Etoposide—urinary bladder cancer	0.0025	0.0025	CcSEcCtD
Betahistine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00248	0.00248	CcSEcCtD
Betahistine—Asthenia—Cisplatin—urinary bladder cancer	0.00246	0.00246	CcSEcCtD
Betahistine—Immune system disorder—Methotrexate—urinary bladder cancer	0.00239	0.00239	CcSEcCtD
Betahistine—Dizziness—Fluorouracil—urinary bladder cancer	0.00239	0.00239	CcSEcCtD
Betahistine—Diarrhoea—Cisplatin—urinary bladder cancer	0.00235	0.00235	CcSEcCtD
Betahistine—Erythema multiforme—Epirubicin—urinary bladder cancer	0.00235	0.00235	CcSEcCtD
Betahistine—Vomiting—Gemcitabine—urinary bladder cancer	0.00234	0.00234	CcSEcCtD
Betahistine—Rash—Gemcitabine—urinary bladder cancer	0.00232	0.00232	CcSEcCtD
Betahistine—Dermatitis—Gemcitabine—urinary bladder cancer	0.00232	0.00232	CcSEcCtD
Betahistine—Hypersensitivity—Etoposide—urinary bladder cancer	0.00232	0.00232	CcSEcCtD
Betahistine—Headache—Gemcitabine—urinary bladder cancer	0.00231	0.00231	CcSEcCtD
Betahistine—Vomiting—Fluorouracil—urinary bladder cancer	0.0023	0.0023	CcSEcCtD
Betahistine—Rash—Fluorouracil—urinary bladder cancer	0.00228	0.00228	CcSEcCtD
Betahistine—Dermatitis—Fluorouracil—urinary bladder cancer	0.00228	0.00228	CcSEcCtD
Betahistine—Headache—Fluorouracil—urinary bladder cancer	0.00227	0.00227	CcSEcCtD
Betahistine—Asthenia—Etoposide—urinary bladder cancer	0.00226	0.00226	CcSEcCtD
Betahistine—Immune system disorder—Epirubicin—urinary bladder cancer	0.00224	0.00224	CcSEcCtD
Betahistine—Pruritus—Etoposide—urinary bladder cancer	0.00222	0.00222	CcSEcCtD
Betahistine—Nausea—Gemcitabine—urinary bladder cancer	0.00219	0.00219	CcSEcCtD
Betahistine—Vomiting—Cisplatin—urinary bladder cancer	0.00218	0.00218	CcSEcCtD
Betahistine—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.00217	0.00217	CcSEcCtD
Betahistine—Rash—Cisplatin—urinary bladder cancer	0.00216	0.00216	CcSEcCtD
Betahistine—Dermatitis—Cisplatin—urinary bladder cancer	0.00216	0.00216	CcSEcCtD
Betahistine—Diarrhoea—Etoposide—urinary bladder cancer	0.00215	0.00215	CcSEcCtD
Betahistine—Nausea—Fluorouracil—urinary bladder cancer	0.00215	0.00215	CcSEcCtD
Betahistine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00214	0.00214	CcSEcCtD
Betahistine—Flatulence—Epirubicin—urinary bladder cancer	0.00213	0.00213	CcSEcCtD
Betahistine—Malaise—Methotrexate—urinary bladder cancer	0.00208	0.00208	CcSEcCtD
Betahistine—Dizziness—Etoposide—urinary bladder cancer	0.00208	0.00208	CcSEcCtD
Betahistine—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00207	0.00207	CcSEcCtD
Betahistine—Nausea—Cisplatin—urinary bladder cancer	0.00204	0.00204	CcSEcCtD
Betahistine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.002	0.002	CcSEcCtD
Betahistine—Convulsion—Methotrexate—urinary bladder cancer	0.002	0.002	CcSEcCtD
Betahistine—Vomiting—Etoposide—urinary bladder cancer	0.002	0.002	CcSEcCtD
Betahistine—Rash—Etoposide—urinary bladder cancer	0.00198	0.00198	CcSEcCtD
Betahistine—Dermatitis—Etoposide—urinary bladder cancer	0.00198	0.00198	CcSEcCtD
Betahistine—Headache—Etoposide—urinary bladder cancer	0.00197	0.00197	CcSEcCtD
Betahistine—Flatulence—Doxorubicin—urinary bladder cancer	0.00197	0.00197	CcSEcCtD
Betahistine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00195	0.00195	CcSEcCtD
Betahistine—Malaise—Epirubicin—urinary bladder cancer	0.00195	0.00195	CcSEcCtD
Betahistine—Discomfort—Methotrexate—urinary bladder cancer	0.00194	0.00194	CcSEcCtD
Betahistine—Confusional state—Methotrexate—urinary bladder cancer	0.0019	0.0019	CcSEcCtD
Betahistine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00188	0.00188	CcSEcCtD
Betahistine—Convulsion—Epirubicin—urinary bladder cancer	0.00187	0.00187	CcSEcCtD
Betahistine—Nausea—Etoposide—urinary bladder cancer	0.00187	0.00187	CcSEcCtD
Betahistine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.00185	0.00185	CcSEcCtD
Betahistine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00185	0.00185	CcSEcCtD
Betahistine—Skin disorder—Methotrexate—urinary bladder cancer	0.00183	0.00183	CcSEcCtD
Betahistine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00183	0.00183	CcSEcCtD
Betahistine—Discomfort—Epirubicin—urinary bladder cancer	0.00182	0.00182	CcSEcCtD
Betahistine—Malaise—Doxorubicin—urinary bladder cancer	0.0018	0.0018	CcSEcCtD
Betahistine—Confusional state—Epirubicin—urinary bladder cancer	0.00178	0.00178	CcSEcCtD
Betahistine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00176	0.00176	CcSEcCtD
Betahistine—Convulsion—Doxorubicin—urinary bladder cancer	0.00173	0.00173	CcSEcCtD
Betahistine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00173	0.00173	CcSEcCtD
Betahistine—Tachycardia—Epirubicin—urinary bladder cancer	0.00172	0.00172	CcSEcCtD
Betahistine—Skin disorder—Epirubicin—urinary bladder cancer	0.00171	0.00171	CcSEcCtD
Betahistine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00169	0.00169	CcSEcCtD
Betahistine—Discomfort—Doxorubicin—urinary bladder cancer	0.00168	0.00168	CcSEcCtD
Betahistine—Dyspnoea—Methotrexate—urinary bladder cancer	0.00168	0.00168	CcSEcCtD
Betahistine—Somnolence—Methotrexate—urinary bladder cancer	0.00167	0.00167	CcSEcCtD
Betahistine—Dyspepsia—Methotrexate—urinary bladder cancer	0.00166	0.00166	CcSEcCtD
Betahistine—Confusional state—Doxorubicin—urinary bladder cancer	0.00164	0.00164	CcSEcCtD
Betahistine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.00163	0.00163	CcSEcCtD
Betahistine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00163	0.00163	CcSEcCtD
Betahistine—Fatigue—Methotrexate—urinary bladder cancer	0.00162	0.00162	CcSEcCtD
Betahistine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.0016	0.0016	CcSEcCtD
Betahistine—Tachycardia—Doxorubicin—urinary bladder cancer	0.00159	0.00159	CcSEcCtD
Betahistine—Skin disorder—Doxorubicin—urinary bladder cancer	0.00158	0.00158	CcSEcCtD
Betahistine—Dyspnoea—Epirubicin—urinary bladder cancer	0.00157	0.00157	CcSEcCtD
Betahistine—Somnolence—Epirubicin—urinary bladder cancer	0.00157	0.00157	CcSEcCtD
Betahistine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00155	0.00155	CcSEcCtD
Betahistine—Dyspepsia—Epirubicin—urinary bladder cancer	0.00155	0.00155	CcSEcCtD
Betahistine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00152	0.00152	CcSEcCtD
Betahistine—Fatigue—Epirubicin—urinary bladder cancer	0.00152	0.00152	CcSEcCtD
Betahistine—Urticaria—Methotrexate—urinary bladder cancer	0.0015	0.0015	CcSEcCtD
Betahistine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.00145	0.00145	CcSEcCtD
Betahistine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00145	0.00145	CcSEcCtD
Betahistine—Somnolence—Doxorubicin—urinary bladder cancer	0.00145	0.00145	CcSEcCtD
Betahistine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00144	0.00144	CcSEcCtD
Betahistine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00141	0.00141	CcSEcCtD
Betahistine—Fatigue—Doxorubicin—urinary bladder cancer	0.00141	0.00141	CcSEcCtD
Betahistine—Urticaria—Epirubicin—urinary bladder cancer	0.0014	0.0014	CcSEcCtD
Betahistine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00139	0.00139	CcSEcCtD
Betahistine—Asthenia—Methotrexate—urinary bladder cancer	0.00135	0.00135	CcSEcCtD
Betahistine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.00134	0.00134	CcSEcCtD
Betahistine—Pruritus—Methotrexate—urinary bladder cancer	0.00133	0.00133	CcSEcCtD
Betahistine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.0013	0.0013	CcSEcCtD
Betahistine—Urticaria—Doxorubicin—urinary bladder cancer	0.0013	0.0013	CcSEcCtD
Betahistine—Diarrhoea—Methotrexate—urinary bladder cancer	0.00129	0.00129	CcSEcCtD
Betahistine—Asthenia—Epirubicin—urinary bladder cancer	0.00126	0.00126	CcSEcCtD
Betahistine—Pruritus—Epirubicin—urinary bladder cancer	0.00125	0.00125	CcSEcCtD
Betahistine—Dizziness—Methotrexate—urinary bladder cancer	0.00125	0.00125	CcSEcCtD
Betahistine—Diarrhoea—Epirubicin—urinary bladder cancer	0.00121	0.00121	CcSEcCtD
Betahistine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.0012	0.0012	CcSEcCtD
Betahistine—Vomiting—Methotrexate—urinary bladder cancer	0.0012	0.0012	CcSEcCtD
Betahistine—Rash—Methotrexate—urinary bladder cancer	0.00119	0.00119	CcSEcCtD
Betahistine—Dermatitis—Methotrexate—urinary bladder cancer	0.00119	0.00119	CcSEcCtD
Betahistine—Headache—Methotrexate—urinary bladder cancer	0.00118	0.00118	CcSEcCtD
Betahistine—Asthenia—Doxorubicin—urinary bladder cancer	0.00117	0.00117	CcSEcCtD
Betahistine—Dizziness—Epirubicin—urinary bladder cancer	0.00117	0.00117	CcSEcCtD
Betahistine—Pruritus—Doxorubicin—urinary bladder cancer	0.00115	0.00115	CcSEcCtD
Betahistine—Vomiting—Epirubicin—urinary bladder cancer	0.00112	0.00112	CcSEcCtD
Betahistine—Nausea—Methotrexate—urinary bladder cancer	0.00112	0.00112	CcSEcCtD
Betahistine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.00112	0.00112	CcSEcCtD
Betahistine—Rash—Epirubicin—urinary bladder cancer	0.00111	0.00111	CcSEcCtD
Betahistine—Dermatitis—Epirubicin—urinary bladder cancer	0.00111	0.00111	CcSEcCtD
Betahistine—Headache—Epirubicin—urinary bladder cancer	0.0011	0.0011	CcSEcCtD
Betahistine—Dizziness—Doxorubicin—urinary bladder cancer	0.00108	0.00108	CcSEcCtD
Betahistine—Nausea—Epirubicin—urinary bladder cancer	0.00105	0.00105	CcSEcCtD
Betahistine—Vomiting—Doxorubicin—urinary bladder cancer	0.00104	0.00104	CcSEcCtD
Betahistine—Rash—Doxorubicin—urinary bladder cancer	0.00103	0.00103	CcSEcCtD
Betahistine—Dermatitis—Doxorubicin—urinary bladder cancer	0.00103	0.00103	CcSEcCtD
Betahistine—Headache—Doxorubicin—urinary bladder cancer	0.00102	0.00102	CcSEcCtD
Betahistine—Nausea—Doxorubicin—urinary bladder cancer	0.000969	0.000969	CcSEcCtD
